We Give Shareholders a Voice

Aerie Pharmaceuticals, Inc. Info Request Form

Levi & Korsinsky announces the filing of a class action lawsuit in the United States District Court for the District of New Jersey on behalf of shareholders who purchased Aerie Pharmaceuticals, Inc. (NASDAQGM: AERI) securities between August 6, 2014 and April 23, 2015.

The complaint alleges that during the Class Period, Aerie Pharmaceuticals made false and misleading statements and/or failed to disclose adverse information regarding the Company’s prospects for Rhopressa. On April 23, 2015, Aerie Pharmaceuticals issued a release announcing that Rhopressa did not meet its “primary efficacy endpoint” in its first Phase 3 registration trial. Upon this news, shares of Aerie Pharmaceuticals fell more than 60 percent to close at $12.87 per share on April 24, 2015. If you suffered a loss in Aerie Pharmaceuticals you have until June 29, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

To receive more information, please fill out the form.

Request More Information

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

This letter confirms that you have retained Levi & Korsinsky, LLP to represent you as a named plaintiff in a shareholder action involving Aerie Pharmaceuticals, Inc.

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other Aerie Pharmaceuticals shareholders.


Levi & Korsinsky,LLP

Joseph Levi

AGREED: Sign Name Clear